Rein Therapeutics Inc.
RNTX
$0.83
-$0.04-4.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.08% | -17.13% | -21.36% | -31.69% | -39.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.75% | -18.72% | -21.99% | -19.75% | -4.60% |
| Operating Income | 14.75% | 18.72% | 21.99% | 19.75% | 4.60% |
| Income Before Tax | 16.84% | 18.94% | 21.49% | -106.66% | -140.65% |
| Income Tax Expenses | 53.89% | 53.89% | 53.89% | -- | -- |
| Earnings from Continuing Operations | 15.87% | 18.06% | 20.69% | -101.38% | -134.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.87% | 18.06% | 20.69% | -101.38% | -134.53% |
| EBIT | 14.75% | 18.72% | 21.99% | 19.75% | 4.60% |
| EBITDA | 14.69% | 18.66% | 21.87% | 19.49% | 4.19% |
| EPS Basic | 40.89% | 37.80% | 46.98% | 15.43% | 17.09% |
| Normalized Basic EPS | 39.96% | 32.88% | 51.88% | 67.96% | 67.46% |
| EPS Diluted | 40.89% | 37.80% | 46.98% | 15.43% | 17.09% |
| Normalized Diluted EPS | 39.96% | 32.88% | 51.88% | 67.96% | 67.46% |
| Average Basic Shares Outstanding | 71.10% | 29.33% | 42.14% | 72.31% | 138.41% |
| Average Diluted Shares Outstanding | 71.10% | 29.33% | 42.14% | 72.31% | 138.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |